Related Experiment Video
Updated: Aug 17, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer
1Department of Hematology, The Urologic Institute, Cleveland Clinic Foundation, OH 44195, USA.
Abstract:
Muscle-invasive bladder cancer is typically an aggressive solid tumor with the propensity for early systemic dissemination. Although radical cystectomy remains the gold standard intervention, the high rate of systemic failure has prompted investigators to evaluate various strategies to attempt to improve survival, including the early administration of systemic chemotherapy. These efforts have provided mixed results with two recently completed trials providing conflicting results. Other strategies include attempts to both preserve the bladder using combinations of limited surgical resection, systemic chemotherapy, and radiotherapy. This review focuses on the potential of neoadjuvantly administered therapies to impact the management of muscle-invasive bladder cancer.
Insights
Neoadjuvant therapies show promise for improving survival in muscle-invasive bladder cancer. This review examines their potential to impact treatment strategies beyond radical cystectomy.
Area of Science:
- Oncology
- Urology
Background:
- Muscle-invasive bladder cancer is aggressive and prone to early metastasis.
- Radical cystectomy is standard but often followed by systemic failure.
- Current treatment strategies aim to improve survival rates.
Purpose of the Study:
- To review the potential of neoadjuvant therapies in managing muscle-invasive bladder cancer.
- To explore strategies beyond radical cystectomy for improved outcomes.
- To assess the impact of neoadjuvant treatments on bladder cancer management.
Main Methods:
- Review of existing literature on neoadjuvant therapies for muscle-invasive bladder cancer.
- Analysis of studies evaluating systemic chemotherapy and bladder preservation strategies.
- Focus on neoadjuvant administration of therapies.
Main Results:
- Radical cystectomy is the gold standard but has limitations.
- Systemic chemotherapy administration has yielded mixed results.
- Conflicting outcomes from recent clinical trials necessitate further investigation.
Conclusions:
- Neoadjuvant therapies offer a potential strategy to improve survival in muscle-invasive bladder cancer.
- Combinations of surgery, chemotherapy, and radiotherapy are being explored for bladder preservation.
- Further research is needed to optimize neoadjuvant treatment protocols.
